UCLA grows off-the-shelf cancer-killing T cells from cord blood

A single dose of ready-made immune cells, grown from a baby's donated cord blood, shrank solid tumors in mice and left the treated animals living longer, without the dangerous donor-cell reaction that has stalled off-the-shelf cancer therapy for a decade.

The result, published this month in Cell Reports Medicine00415-5) by a UCLA team led by Lili Yang of the Eli and Edythe Broad Stem Cell Research Center and the Jonsson Comprehensive Cancer Center, is the latest attempt to address two bottlenecks that have slowed off-the-shelf T-cell therapy for years: the weeks of personalized manufacturing that current treatments require, and the safety problem that comes from giving a patient someone else's immune cells.

T cells are the immune system's cancer-killing specialists. Existing therapies either pull them out of a patient, retrain them to recognize a tumor, and put them back, a process that costs hundreds of thousands of dollars and runs on a per-patient schedule, or, in newer "off-the-shelf" versions, use donor cells. The donor route is faster and cheaper in principle, but it has run into a wall: donor T cells can mistake the patient's body for a target, causing graft-versus-host disease, a condition in which the transplanted cells attack the recipient's healthy tissue.

The UCLA team's design starts earlier than usual. They engineer the T-cell receptor, the surface protein that recognizes a specific cancer target, at the stem-cell stage, while the cells are still hematopoietic stem cells, blood-forming cells collected from a newborn's umbilical cord. Every T cell that grows out of those engineered stem cells carries essentially one receptor, the new cancer-specific one, rather than the random mix a normal T cell develops. That means the cells do not need extra gene editing to silence the receptors they would have made on their own, and it cuts the graft-versus-host risk that has dogged earlier off-the-shelf T-cell programs.

To handle tumors that try to dodge recognition, the team also kept a second detection system intact: the natural killer cell receptors, or NKRs, that allow T cells to attack when the main target protein is missing. The product, called AlloESO-T, targets NY-ESO-1, a cancer-testis antigen found on several solid tumors but not on most healthy adult tissue. It is described in the paper00415-5) and in the UCLA Health Sciences release.

In mice bearing ovarian cancer or melanoma, a single infusion of AlloESO-T cells controlled tumor growth and extended survival. A comparison arm, T cells engineered using the standard peripheral-blood method, only partially controlled the tumors and triggered a graft-versus-host-like syndrome, with the cells trafficking to liver and lung rather than to the tumor. The cord-blood-derived cells expanded roughly 100-fold in the mice, homed to the tumors, and persisted for weeks while leaving healthy organs alone, according to the release.

From one small cord-blood donation, the researchers say they can grow trillions of therapeutic cells in about six weeks, enough, they estimate, for thousands of patient doses at roughly $5,000 each, a fraction of the six-figure cost of personalized T-cell therapy. The cells can be stored and drawn as needed, the way a blood bank works.

That math is a researcher estimate, not an independently validated cost. The result is also preclinical: no human trial, no FDA review, no data on whether the dual-receptor design will hold up in people. The field has produced many such preclinical T-cell advances that did not translate. CAR T-cell therapy, a related treatment in which immune cells are reprogrammed to see a marker on the outside of a cancer cell, took more than a decade of clinical work to reach solid tumors, and the broader category of off-the-shelf T-cell therapy has been slowed repeatedly by safety setbacks. A single Cell Reports Medicine paper, in mice, is the floor of the evidence, not the ceiling.

The UCLA group presents AlloESO-T as a modular platform: the NY-ESO-1 receptor can in principle be swapped for any validated cancer-targeting receptor, and the work builds on the Yang lab's prior CAR-NKT programs and on the UCLA Health Center for Advanced Biotherapies. The paper00415-5) and independent ACIR indexing of the same study confirm authorship and scope; the underlying numerical data, including tumor-volume curves, survival days, and the NKR-versus-TCR-only arms, is in the paper itself, not in the press release. Watch items: a larger-animal study, the first-in-human safety readout, and which solid-tumor targets the lab tries next.

Funding came from the California Institute for Regenerative Medicine, the UCLA Molecular Biology Institute, the UCLA Office of the Chancellor, and the UCLA Goodman-Luskin Microbiome Center.